New drug aims to cut steroid use in lung sarcoidosis
Disease control
Completed
This Phase 3 trial tested a drug called efzofitimod in 268 adults with pulmonary sarcoidosis, a condition that causes lung inflammation. Participants received either the drug or a placebo every 4 weeks for 48 weeks. The main goal was to see if the drug could help people safely re…
Phase: PHASE3 • Sponsor: aTyr Pharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC